GLP-1 vs GLP-3: Clarifying the Terminology Before Comparing Outcomes
A patient walks into a medical weight-loss clinic holding up a phone screen and asks to be switched from semaglutide to "the new GLP-3 shot" she saw discussed in a private Facebook group. The front-desk staff has never heard the term, the prescribing clinician has never heard the term, and a quick literature search turns up nothing under that exact name. This scenario is increasingly common in clinics running high patient volume on GLP-1 receptor agonists, and it is worth addressing directly before any efficacy or safety comparison can be made.
There is no endogenous hormone or FDA-recognized drug class called "GLP-3." Glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) are both real proglucagon-derived peptides with distinct receptors; no third GLP isoform has been characterized in human physiology. When the term "GLP-3 analogue" surfaces in patient forums, supplement-seller marketing, or informal clinician discussion, it is almost always being used as shorthand for unimolecular multi-receptor agonists — compounds engineered to activate the GLP-1 receptor alongside one or more additional incretin or glucagon-family receptors in a single molecule. Retatrutide, the most clinically advanced compound in this category, activates GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors (GLP-1R/GIPR/GCGR triple agonism).
This distinction matters for anyone evaluating the literature, because searching "GLP-3" in PubMed or ClinicalTrials.gov returns nothing relevant, while searching "triple agonist" or "unimolecular multi-agonist" returns an active and fast-moving trial pipeline. For the remainder of this review, "GLP-3 analogue" is treated as the informal industry label for triple-receptor agonists such as retatrutide, benchmarked against single-target GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide).
Receptor Pharmacology: Single-Target vs Multi-Receptor Agonism
Semaglutide is a GLP-1 receptor-selective agonist with roughly 94% sequence homology to native human GLP-1, extended via albumin-binding fatty-acid acylation to a half-life of approximately 165–184 hours, which supports once-weekly dosing. Its potency at the GLP-1 receptor is high, with reported EC50 values in the low picomolar-to-nanomolar range depending on assay conditions, driving downstream cAMP signaling in pancreatic beta cells that potentiates glucose-dependent insulin secretion.
Tirzepatide is a dual agonist engineered from a GIP backbone with GLP-1 receptor activity grafted on; published receptor-binding data (Coskun et al., Mol Metab 2018) show it is GIP-receptor biased, with GIP receptor potency approximating native GIP and GLP-1 receptor potency roughly fivefold lower than native GLP-1 in cAMP assays — a "balanced but GIP-leaning" profile that appears to reduce GLP-1-pathway-driven nausea at comparable weight-loss magnitude.
Retatrutide extends this logic a step further by adding glucagon receptor agonism to the GIP/GLP-1 backbone. Glucagon receptor activation increases hepatic glucose output and energy expenditure independent of appetite suppression, which is the pharmacological rationale for the larger weight-loss effect sizes seen in early trials — though it also introduces a theoretical counterbalance to glycemic control that trial designs have had to account for. A fuller breakdown of receptor kinetics and why they predict tolerability is covered in GLP-1 Receptor Mechanism of Action: Why the Pharmacology Predicts Tolerability.
Efficacy Data: Head-to-Head and Placebo-Controlled Weight Loss Outcomes
The numbers a clinic owner needs on a whiteboard are these. In STEP 1 (NCT03548935, n=1,961), semaglutide 2.4 mg weekly produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (Wilding et al., NEJM 2021, PMID 33567185). In SURMOUNT-1 (NCT04184622, n=2,539), tirzepatide 15 mg weekly produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (Jastreboff et al., NEJM 2022, PMID 35658024). In the phase 2 retatrutide trial (NCT04881903, n=338), the 12 mg dose produced 24.2% mean weight loss at 48 weeks, with some individual participants exceeding 30% (Jastreboff et al., NEJM 2023, PMID 37366315).
The direct head-to-head data clinicians should weight most heavily comes from SURMOUNT-5, which compared tirzepatide against semaglutide in the same trial population rather than relying on cross-trial comparison — a methodologically important distinction, since baseline BMI, attrition, and follow-up duration differ across the STEP and SURMOUNT programs. That trial's design and results are detailed in Tirzepatide vs Semaglutide: Head-to-Head Weight Loss Trial Data from SURMOUNT-5.
No completed phase 3 trial has directly compared retatrutide against tirzepatide or semaglutide head-to-head; all retatrutide efficacy data to date comes from a single phase 2 program, with phase 3 (the TRIUMPH program) still enrolling as of this writing. Full dosing arms and secondary endpoints from that phase 2 dataset are broken down in Retatrutide Phase 2 Trial Results: What the 48-Week Data Shows for Weight and Glycemic Endpoints.
Glycemic Endpoints and Type 2 Diabetes Sub-Populations
Weight-loss magnitude is only half the clinical picture; glycemic control is the other half that drives payer decisions and trial design in mixed populations. In participants with type 2 diabetes, semaglutide 2.4 mg (STEP 2 data) produced HbA1c reductions around 1.6 percentage points, while tirzepatide's SURPASS program showed HbA1c reductions up to 2.07 percentage points at the 15 mg dose in drug-naive populations.
Retatrutide's phase 2 diabetic sub-cohort showed HbA1c reductions in a comparable 2.0 percentage-point range at higher doses, though the sample size in that sub-group (n≈135 across dose arms) is far smaller than the diabetic populations studied in the SURPASS or SUSTAIN programs, and confidence intervals are correspondingly wider.
A few things clinics tracking these sub-populations should note when counseling patients with concurrent type 2 diabetes:
- Glucagon receptor agonism in retatrutide theoretically raises hepatic glucose output, but net glycemic effect in trials so far has remained favorable — this should be monitored, not assumed, in individual patients.
- Attrition in diabetic sub-cohorts tends to run higher than in non-diabetic weight-management cohorts across all three compound classes, often 10–15% versus 6–9%, which affects how confidently trial-level averages generalize to a real clinic population.
- Baseline HbA1c above 8.0% appears associated with larger absolute reductions across all compounds studied, a regression-to-the-mean pattern that should temper expectations set with lower-baseline patients.
Safety and Tolerability: Adverse Event Profiles Compared
Gastrointestinal adverse events dominate the safety profile of every compound in this comparison. Nausea was reported in roughly 44% of semaglutide-treated participants in STEP 1, 33–36% of tirzepatide-treated participants in SURMOUNT-1 depending on dose, and up to 47% of participants at the highest retatrutide dose in the phase 2 trial. Discontinuation due to adverse events ran approximately 7% in STEP 1, 7.1% in SURMOUNT-1, and as high as 16% in the retatrutide 12 mg arm — the clearest signal that tolerability, not just efficacy, scales with the number of receptors engaged.
The mechanistic reason nausea tracks with GLP-1 pathway engagement — delayed gastric emptying and central area postrema signaling — is covered in detail in GLP-1 Receptor Agonists and Gastric Emptying: The Mechanism Behind Nausea, which is worth reviewing before setting patient expectations on dose-titration timelines.
Contraindications are shared across the class: personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, and a history of severe hypersensitivity reaction. Because retatrutide has only phase 2 exposure data (48 weeks, several hundred participants) compared to the tens of thousands of patient-years now accumulated on semaglutide and tirzepatide post-approval, rare adverse events with an incidence below roughly 1-in-1,000 would not yet be reliably detectable in the retatrutide dataset. That gap is a monitoring consideration, not a reason to assume equivalent safety.
Cardiovascular and Renal Outcome Data
Weight loss percentage is not the only number that should drive a prescribing decision, particularly in patients with established cardiovascular or renal risk. The SELECT trial (NCT03574597, n=17,604) found semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% versus placebo in patients with established cardiovascular disease and overweight or obesity but without diabetes (Lincoff et al., NEJM 2023, PMID 37952131). Four-year follow-up data and sub-population signals from that trial are reviewed in GLP-1 Cardiovascular Outcomes: SELECT Trial Four-Year Follow-Up Data Review.
On the renal side, the FLOW trial (NCT03819153) demonstrated a 24% relative risk reduction in a composite kidney-disease progression endpoint with semaglutide in patients with type 2 diabetes and chronic kidney disease, a result detailed in Renal Function and GLP-1 Receptor Agonists: FLOW Trial Kidney Endpoint Analysis.
Neither tirzepatide nor retatrutide has completed a dedicated cardiovascular or renal outcomes trial as of this review. A tirzepatide cardiovascular outcomes trial is ongoing, and no retatrutide outcomes trial of comparable scale has been registered. For a patient with prior myocardial infarction or stage 3 chronic kidney disease, this means semaglutide currently carries the strongest outcomes evidence base independent of its weight-loss effect size — a distinction that should factor into compound selection at least as heavily as percentage body-weight change.
Dosing, Titration, and Administration Practicalities
Operationally, dose titration is where most clinic complaints originate, and the schedules differ meaningfully across compounds. Semaglutide for weight management follows a stepped titration from 0.25 mg to a 2.4 mg maintenance dose over roughly 16–20 weeks, front-loading low doses specifically to blunt early nausea. Evidence-based titration protocols pulled directly from the pivotal trial designs are laid out in Semaglutide Dose Titration Schedules: Evidence-Based Protocols from Pivotal Trials.
Tirzepatide follows a similar stepped approach from 2.5 mg to a maximum 15 mg maintenance dose, also over about 20 weeks, with dose increases typically held or slowed when GI tolerability lags.
Retatrutide dosing in the phase 2 trial ranged up to 12 mg weekly, but there is no FDA-approved product, no approved titration schedule, and no legitimate prescription pathway outside of clinical trial enrollment at this time. Any product marketed as retatrutide for individual purchase outside a registered trial falls into unregulated "research use only" territory, with no chain-of-custody, sterility, or potency assurance comparable to an FDA-inspected manufacturing process. Clinics fielding patient requests for it should be direct about that gap rather than deferring the question.
Access, Cost, and Regulatory Status in Real-World Practice
Semaglutide (marketed as Wegovy for chronic weight management) and tirzepatide (marketed as Zepbound) are both FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related comorbidity. Retatrutide holds no FDA approval in any indication and remains an investigational compound restricted to sponsor-run clinical trials.
Cash-pay pricing for the approved brand-name injectables commonly runs $1,000–$1,350 per month without insurance coverage, and payer coverage varies widely by plan, employer carve-out, and diagnosis coding. Compounded versions of semaglutide have circulated at lower price points during periods of branded-drug shortage, but they carry distinct sterility, potency-verification, and stability considerations that differ meaningfully from FDA-approved formulations — a comparison worth reading in full before recommending either path, covered in Compounded Semaglutide vs FDA-Approved Brands: Stability and Sterility Considerations.
Peptide-seller sites that advertise retatrutide or other "research-only" triple agonists for individual purchase are operating outside the same regulatory framework that governs Wegovy or Zepbound manufacturing, labeling, and quality control. A clinic asked to source or administer such a product is taking on liability that has no analogue in prescribing an FDA-approved medication under label.
Clinical Decision-Making: Which Class Fits Which Patient Profile
In practice, compound selection comes down to a short list of concrete variables rather than which drug produced the largest headline weight-loss percentage. Established cardiovascular disease or chronic kidney disease points toward semaglutide, given its unique outcomes-trial evidence base from SELECT and FLOW. A primary need for larger weight-loss magnitude in a patient without significant GI sensitivity, and for whom cost and access are not limiting, may make tirzepatide a reasonable next step given its larger effect size relative to semaglutide in SURMOUNT-5.
Retatrutide, absent FDA approval, is not a first-line — or currently accessible — option outside of trial enrollment, regardless of how favorable its phase 2 numbers look on paper. Presenting it to a patient as an available "next-generation" option overstates what is actually obtainable through a licensed prescriber today.
Monitoring across all three compound classes should include baseline and periodic renal function, attention to gallbladder symptoms (biliary disease risk appears modestly elevated with rapid weight loss on this drug class), and lipase or clinical symptoms suggestive of pancreatitis. Persistent severe abdominal pain radiating to the back, signs of gallbladder obstruction (jaundice, right-upper-quadrant pain with fever), or symptoms of a hypersensitivity reaction warrant immediate clinician contact rather than waiting for the next scheduled visit.
What's Still Unknown: Gaps in the Head-to-Head Evidence
No completed randomized controlled trial has directly compared retatrutide against tirzepatide, which means every retatrutide-versus-established-therapy comparison in circulation today is a cross-trial comparison — useful for hypothesis generation, not for clinical decision-making with the same confidence as a head-to-head design like SURMOUNT-5. The TRIUMPH phase 3 program is expected to generate that head-to-head data over the next several years, alongside longer follow-up on durability of weight loss after treatment discontinuation.
Long-term data beyond roughly one to two years remains thin for all three compound classes when it comes to bone density, lean mass preservation, and behavior after treatment withdrawal — an area covered from the semaglutide side in GLP-1 Discontinuation and Weight Regain: STEP 4 Long-Term Follow-Up Findings. Until multi-year outcomes and lean-mass data mature for triple agonists specifically, treating retatrutide-class compounds as a settled substitute for GLP-1 receptor agonists in routine practice is not supported by the current evidence base.
For a clinic building a weight-management protocol today, the actionable step is straightforward: base compound selection on FDA-approved options with the strongest matching outcomes evidence for the individual patient's risk profile, document the specific trial data used to support that choice, and revisit the decision as phase 3 triple-agonist data matures rather than adopting unapproved compounds on the basis of phase 2 headlines alone.
This article summarizes research and does not constitute medical advice. Consult a licensed clinician for diagnosis, treatment, or any decisions about medications or supplements.